Therapeutics of bortezomib, carfilzomib, and ixazomib in proteases-induced cancer
Therapeutics of Natural and Synthetic Compounds in Protease-Induced Cancer, Elsevier, ss.623-640, 2025
- Yayın Türü: Kitapta Bölüm / Araştırma Kitabı
- Basım Tarihi: 2025
- Doi Numarası: 10.1016/b978-0-443-26635-5.00041-9
- Yayınevi: Elsevier
- Sayfa Sayıları: ss.623-640
- Anahtar Kelimeler: Bortezomib, cancer, carfilzomib, ixazomib, proteasome inhibitors
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Cancerous diseases associated with proteases, like proteolytic enzymes are found in great number or activity is altered beyond physiological levels. Numerous cellular functions, including cell death, cellular growth, and protein degradation depend on these endogenous proteolytic enzymes, which are easily differentiable and these enzymes are usually overexpressed in cancer pathogenesis. Imbalance in these enzymes greatly enhances cancer development, the spread of cancer cells in various organs, and combating cancer therapies. This review presents some important therapeutic approaches for cancer treatment based on inhibition of the ubiquitin-proteasome system, with a particular focus on proteasome inhibitors bortezomib, carfilzomib, and ixazomib. Through the alteration of apoptosis, such “nuclear” activity proves particularly useful in the case of some cancers like multiple myeloma (MM), where active cycle-arresting drugs are required. Then, the proteolytic activities of various molecular infective components such as cysteine cathepsins, serines, and metallo or matrix metalloproteinases that cause the spread and infiltration of the tumor have also been reviewed. Preventing resistance in flow cytometry drug screening remains a critical issue that will help optimize cancer therapy being undertaken today. This review focuses on the promise of protease inhibition strategies in the treatment of cancers and improving the lifespan of patients.